Parabilis director granted 20K stock options

Q: What insider transaction did PBLS director Craig Tendler report on this Form 4?

Craig Tendler reported the grant of 20,294 stock options for Parabilis Medicines, Inc. (PBLS) on August 22, 2026. The options are a compensation-related award, not a market purchase or sale of common shares.

Q: What is the exercise price of the stock options granted to the PBLS director?

The stock options granted to Craig Tendler have an exercise price of $39.36 per share. Each option allows the holder to buy one share of PBLS common stock at this price once the option is vested and exercisable.

Q: How many PBLS stock options did Craig Tendler hold after this transaction?

After the reported grant, Craig Tendler held 20,294 stock options for PBLS as directly owned derivative securities. This figure reflects the total derivative holdings reported following the transaction.

Q: When do Craig Tendler’s PBLS stock options start vesting and over what period?

The options start vesting on August 22, 2026 and will vest in 36 equal monthly installments. Vesting is subject to Dr. Tendler’s continued service on each vesting date.

Q: Was the PBLS Form 4 transaction reported under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 checkbox is not affirmed, and there is no footnote stating that this grant was made pursuant to a Rule 10b5-1 trading plan.

Parabilis Medicines, Inc. (PBLS) reported that director Craig Tendler received a grant of 20,294 stock options on August 22, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Parabilis Medicines, Inc. (PBLS) reported that director Craig Tendler received a grant of 20,294 stock options on August 22, 2026. The options carry an exercise price of $39.36 per share and expire on August 21, 2036. According to the grant terms, the options will vest in 36 equal monthly installments starting August 22, 2026, conditioned on Dr. Tendler’s continued service, resulting in post-transaction direct beneficial ownership of 20,294 derivative securities.

Insider Trade Summary

Grant/Award: 20,294 shares

Grant/Award 1 txn

Insider Tendler Craig

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	20,294	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,294 contracts (Direct)

Footnotes (1)

F1. The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from August 22, 2026, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Stock options granted: 20,294 options Exercise price: $39.36 per share Expiration date: August 21, 2036 +2 more

5 metrics

Stock options granted 20,294 options Grant to Craig Tendler on August 22, 2026

Exercise price $39.36 per share Exercise price for the 20,294 stock options

Expiration date August 21, 2036 Expiration of the granted stock options

Underlying common stock 20,294 shares Shares of PBLS common stock underlying the options

Vesting schedule 36 equal monthly installments Vesting commencing August 22, 2026, subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, vesting, derivative securities

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 39.3600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to this option shall vest and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"reported as a derivative transaction and derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PBLS director Craig Tendler report on this Form 4?

Craig Tendler reported the grant of 20,294 stock options for Parabilis Medicines, Inc. (PBLS) on August 22, 2026. The options are a compensation-related award, not a market purchase or sale of common shares.

What is the exercise price of the stock options granted to the PBLS director?

The stock options granted to Craig Tendler have an exercise price of $39.36 per share. Each option allows the holder to buy one share of PBLS common stock at this price once the option is vested and exercisable.

How many PBLS stock options did Craig Tendler hold after this transaction?

After the reported grant, Craig Tendler held 20,294 stock options for PBLS as directly owned derivative securities. This figure reflects the total derivative holdings reported following the transaction.

When do Craig Tendler’s PBLS stock options start vesting and over what period?

The options start vesting on August 22, 2026 and will vest in 36 equal monthly installments. Vesting is subject to Dr. Tendler’s continued service on each vesting date.

When do the PBLS stock options granted to Craig Tendler expire?

The stock options granted to Craig Tendler are scheduled to expire on August 21, 2036. Any unexercised options after this date will lapse according to the grant terms.

Was the PBLS Form 4 transaction reported under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 checkbox is not affirmed, and there is no footnote stating that this grant was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/25/2026 - 06:15 PM EDT Accepted by SEC EDGAR 08/25/2026 - 06:14 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tendler Craig

(Last)

(First)

(Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE

MASSACHUSETTS

02140

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$39.36	08/22/2026		A		20,294		⁽¹⁾	08/21/2036	Common Stock	20,294	$0.00	20,294	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from August 22, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Teresa Jurgensen, Attorney-in-Fact	08/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR